|
|
|
| This article has been cited by | | 1 | Dosage optimization of clopidogrel via a precision medicine approach: the way forward | | | Sasidharan Pillai V Aswathy,Kotha Rohith Chandra,Pakkath Jyothikrishna,Kanniappan Parthasarathy Arun | | Pharmacogenomics.2022;23(3)195 | | [DOI] | | | 2 | Influence of CYP450 Enzymes, CES1, PON1, ABCB1, and P2RY12 Polymorphisms on Clopidogrel Response in Patients Subjected to a Percutaneous Neurointervention | | | Miriam Saiz-Rodríguez,Carmen Belmonte,José Luis Caniego,Dora Koller,Pablo Zubiaur,Eduardo Bárcena,Daniel Romero-Palacián,Andy R. Eugene,Dolores Ochoa,Francisco Abad-Santos | | Clinical Therapeutics.2019;41(6)1199 | | [DOI] | | | 3 | CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han | | | Jie-Ya Wang,Yan-Jiao Zhang,He Li,Xiao-Lei Hu,Mu-Peng Li,Pei-Yuan Song,Qi-Lin Ma,Li-Ming Peng,Xiao-Ping Chen | | Gene.2018;678(6)226 | | [DOI] | | | 4 | Cardiovascular Risk Reduction | | | Troy J. Smith,Jessica L. Johnson,Abiy Habtewold,Melissa A. Burmeister | | Critical Care Nursing Clinics of North America.2019;31(1)15 | | [DOI] | |
|
